T. Rowe Price Investment Management
KRTX

T. Rowe Price Investment Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

T. Rowe Price Investment Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,709,629
Closed -$858M – 668
2023
Q4 		$858M Sell
2,709,629
-32,828
-1% -$6.38M 0.56% 48
2023
Q3 		$464M Buy
2,742,457
+263,422
+11% +$49.5M 0.33% 97
2023
Q2 		$538M Sell
2,479,035
-1,730
-0.1% -$371K 0.37% 79
2023
Q1 		$451M Buy
2,480,765
+1,278,134
+106% +$244M 0.32% 92
2022
Q4 		$236M Buy
1,202,631
+229,374
+24% +$49.2M 0.18% 138
2022
Q3 		$219M Buy
+973,257
New +$197M 0.17% 136

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

T. Rowe Price Investment Management's KRTX Position: Q1 2024 in Review

T. Rowe Price Investment Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 2,709,629 shares — an estimated $858M sold.

T. Rowe Price Investment Management first reported a position in KRTX in Q3 2022 and held it in 6 quarters. The position peaked at $858M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • T. Rowe Price Investment Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 2,709,629 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $858M.
  • T. Rowe Price Investment Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 6 quarters.
  • T. Rowe Price Investment Management's Karuna Therapeutics, Inc. Common Stock position peaked at $858M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2024, filed 15 May 2024.